Healthcare

Massive Growth of Global Psychedelic Drugs Market Forecast By 2025 | COMPASS, The Emmes Company, LLC, Klarisana, AstraZeneca, F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited

Psychedelic Drugs Market

This Psychedelic Drugs market analysis offers an examination of a range of segments that are relied upon to witness the quickest development amid the estimate forecast frame. A complete discussion about numerous market related topics in this Psychedelic Drugs market research report is sure to aid the client in studying the market on competitive landscape. The company profiles of all the key players and brands that are dominating the Psychedelic Drugs market with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. This report also gives an idea about consumer’s demands, preferences, and their altering likings about particular product.

Global Psychedelic drugs market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of depression worldwide and increase in special designation from the regulatory authorities to the company to expedite the development process are the key factors for market growth.

Psychedelic drugs are also known as psychedelics are the class of hallucinogenic drugs including both classic hallucinogens as well as dissociative drugs that are used recreationally, to alter and enhance the  sensory perception, elevate the mood swings, thought process, energy level promoting spiritual experiences. Psychedelic drugs have been used experimentally for psychological treatment and are able to control mind hence maintaining peace.

Key Market Players: COMPASS, The Emmes Company, LLC, Klarisana,  AstraZeneca, F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc, Mylan N.V. , Merck & Co., Inc, Alkermes, ALLERGAN, H. Lundbeck A/S among others.

REQUEST FOR SAMPLE PDF OF REPORT @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-psychedelic-drugs-market

Market Drivers

  • Increase in the prevalence of depression worldwide can act as a driver for the growth of this market
  • Treatment for psychedelic drugs dependency can also boost the market growth
  • Changing  life style and requirement for enhanced and better life quality is propelling the market growth
  • Increase special designation from the regulatory authority can drive the market growth

According to the statistic published in our World in Data 2017, the global burden of mental and substance use disorders were 122.76 million. Increase cases of mental disorders and accelerating demand of novel therapies are the drivers promoting the growth of this market.

Segmentation: Global Psychedelic Drugs Market

By Application

  • Major Depressive Disorder
  • Resistant depression
  • Panic disorder
  • Post-traumatic stress disorder
  • Opiate Addiction
  • Others

By Drugs

  • Lysergic Acid Diethylamide (LSD)
  • 3,4-Methyl​Enedioxy​Methamphetamine (Ecstasy)
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Ketamine
  • Ayahuasca
  • Salvia
  • Psilocybin
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Inhalation

By Distribution Channel

  • Direct Retailers
  • Online Pharmacies
  • Others

 By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific

DOWNLOAD PDF COPY OF TABLE OF CONTENT @ https://databridgemarketresearch.com/toc/?dbmr=global-psychedelic-drugs-market

Key Developments in the Market:

  • In October 2018, COMPASS received Breakthrough Therapy designation from the FDA for psilocybin therapy for the treatment of resistant depression. With Breakthrough Therapy designation, company can obtain all fast track designation features and FDA commitment and guidance ensuring efficient drug development programme
  • In August 2018, COMPASS received new drug application approval from the FDA for the psilocybin therapy for the treatment of resistant depression. If the trial is successful, it will change the treatment landscape of patients suffering from resistant depression

Competitive Analysis:

Global psychedelic drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global psychedelic drugs market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

INQUIRE | FOR MORE INFORMATION ON THIS REPORT @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-psychedelic-drugs-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Sopan Gedam

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Close